Postpartum Depression

Also known as: Depression, Postpartum / Puerperal depression / Depression puerperal / Postnatal blues / Depression postpartum (excl psychosis) / Postnatal depression (excl psychosis)

DrugDrug NameDrug Description
DB11859BrexanoloneAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females [F4066]. Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening condition [F4072]. Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083]. The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) in postpartum women susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone [F4063]. And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care [L5750].
DrugDrug NamePhaseStatusCount
DB11133Omega-3 fatty acids2Completed1
DB00107Oxytocin2Enrolling by Invitation1
DB01373Calcium2 / 3Terminated1
DB00813Fentanyl2 / 3Recruiting1
DB08917Ferric carboxymaltose2 / 3Terminated1
DB01592Iron2 / 3Terminated1
DB00454Meperidine2 / 3Recruiting1
DB06690Nitrous oxide2 / 3Recruiting1
DB09140Oxygen2 / 3Recruiting1
DB00899Remifentanil2 / 3Recruiting1
DB00296Ropivacaine2 / 3Recruiting1
DB00482Celecoxib3Not Yet Recruiting1
DB01221Ketamine4Not Yet Recruiting1
DB00297BupivacaineNot AvailableRecruiting1
DB00476DuloxetineNot AvailableWithdrawn1
DB01175EscitalopramNot AvailableCompleted2
DB00783EstradiolNot AvailableCompleted1
DB00813FentanylNot AvailableRecruiting1
DB00014GoserelinNot AvailableCompleted1
DB00007LeuprolideNot AvailableCompleted1
DB00653Magnesium sulfateNot AvailableActive Not Recruiting1
DB14158Microcrystalline celluloseNot AvailableTerminated1
DB00107OxytocinNot AvailableUnknown Status1
DB00175PravastatinNot AvailableCompleted1
DB00396ProgesteroneNot AvailableCompleted1
DB01224QuetiapineNot AvailableCompleted1
DB01104SertralineNot AvailableCompleted1
DB01104SertralineNot AvailableTerminated1
DB09153Sodium chlorideNot AvailableCompleted1